MannKind Corporation Release: Type 2 Diabetes Patients On Technosphere Insulin Exhibited No Adverse Effect On Pulmonary Function With Significant HbA1c Reductions, And Showed Significant Weight Reduction Compared To Injected Insulin Analog

VALENCIA, Calif., Sept. 18 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD - News) announced on Saturday, September 16, 2006 at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen results from its Phase 3 clinical study of inhaled insulin in patients with Type 2 diabetes. This study was designed to evaluate whether the MannKind Technosphere® Insulin System showed similar safety and efficacy compared to patients treated with insulin aspart (NovoLog®), an injected rapid-acting insulin analog (RAA).